Highlights and Quick Summary
- EPS (Diluted, from Cont. Ops) for the quarter ending March 31, 2022 was $-1.12 (a 370.13% increase compared to previous quarter)
- Year-over-year quarterly EPS (Diluted, from Cont. Ops) increased by 302.08%
- Annual EPS (Diluted, from Cont. Ops) for 2021 was $1.41 (a -357.24% decrease from previous year)
- Annual EPS (Diluted, from Cont. Ops) for 2020 was $-0.549 (a 48.89% increase from previous year)
- Annual EPS (Diluted, from Cont. Ops) for 2019 was $-0.369 (a -23.15% decrease from previous year)
- Twelve month EPS (Diluted, from Cont. Ops) ending March 31, 2022 was $-1.86 (a 113.2% increase compared to previous quarter)
- Twelve month trailing EPS (Diluted, from Cont. Ops) decreased by -5.22% year-over-year
Trailing EPS (Diluted, from Cont. Ops) for the last four month:
| 31 Mar '22 | 30 Sep '21 | 31 Mar '21 | 31 Mar '20 |
|---|---|---|---|
| $-1.86 | $-0.871 | $-1.28 | $-1.96 |
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EPS (Diluted, from Cont. Ops) of Biofrontera AG Sponsored ADR
Most recent EPS (Diluted, from Cont. Ops)of BFAGY including historical data for past 10 years.Interactive Chart of EPS (Diluted, from Cont. Ops) of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR EPS (Diluted, from Cont. Ops) for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | – | – | $0.0 | – |
| 2021 | – | – | $0.0 | $0.0 | $0.0 |
| 2020 | – | – | – | $0.0 | $0.0 |
| 2019 | – | – | – | $0.0 | $0.0 |
| 2018 | – | – | – | $0.0 | $0.0 |
| 2017 | – | – | $0.0 | $0.0 | $0.0 |
| 2016 | $0.0 | – | – | – | $0.0 |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic